ALDA news today:
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 6, 2011) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH - News; OTCQB:APCSF) ("ALDA") has been notified that the Canadian Intellectual Property Office ("CIPO") has accepted ALDA's patent application that describes the composition, production methods and certain therapeutic uses for ALDA's T36® formulation.
In addition, the Company has two patents issued in the both the US and Australia, one issued in China and one pending in both China and the EU. An additional patent application, seeking protection for the T36® formula in combination with anesthetics, analgesics and anti-inflammatories for the treatment of a wide range of topical infections has been filed in the US and the EU.
Dr. Terrance Owen, President & CEO, states, "Notification that the patent will now be issued in Canada provides further evidence that our intellectual property is very robust. We are gratified to see rapid allowance of the patent applications in a number of jurisdictions. Clearly, ALDA's T36® formulation is unique and is a significant asset to the company."
